

The Pharma QC column: OROSIL C18

Products and services to facilitate analytical methods development


Orochem Technologies Inc.


he QC for the pharmaceutical industry is based on methods developed on a variety of columns. At Orochem, we have attempted to address method development utilizing unique chemistries such as the OROSIL C18 to analyze a wide range of acidic, basic, and neutral compounds. Data is presented on a few representative compounds and unique separation criteria with their associated chromatograms.

Conclusion


We have successfully developed methods for more than 25 analytes with the Orosil C18 column. The OROSIL C18 chemistry provides a unique platform for the analytes currently targeted by the pharma industry towards major diseased states.


Tamoxifen - an orally active selective estrogen receptor modulator







Budesonide - a glucocorticoid steroid







Eprosartan (Teveten)- an angiotensin II receptor antagonist






Ciprofloxacin - a generic antibiotic






Acetonitrile: Buffer 13:87 @ 1.5 mL/min Buffer is 25 mM phosphate buffer at pH 3 with triethylamine 20 μL injection detected at 303 nm


Pregabalin (Lyrica) - an anticonvulsant




Eszopicione (Lunesta) - a nonbenzodiazepine sedative



Stavudine (Zerit) - a nucleoside analog reverse transcriptase inhibitor (NARTI) active against HIV.





(A) Buffer:Acetonitrile:water::75:20:5 and (B) Buffer:Acetonitrile:water::50:20:30 with a gradient of 80% A to 5 minutes and a ramp of 4%/min B for 10 min, hold for 10 min, ramp to 100% B in 5 min and equilibrate to starting conditions for 5 minutes

Buffer is 1.02 % (w/v) KH2PO4 and pH 3.1

Figure 1: Separation methods developed on representative acidic, basic, and neutral molecules using the OROSIL C18 column.